News >

Melflufen Continues to Impress in Heavily Pretreated Myeloma, FDA Submission Coming Soon

Jason M. Broderick @jasoncology
Published: Thursday, Mar 26, 2020

blood cellsMelflufen in combination with dexamethasone induced a 26% overall response rate (ORR) in patients with triple-class refractory multiple myeloma, according to final topline results from the pivotal phase II HORIZON study announced by Oncopeptides AB, the developer of the first-in-class anticancer peptide-drug conjugate.1

Regarding toxicity, grade 3/4 adverse events were mainly hematologic, and the occurrence of nonhematologic AEs was infrequent.


  1. Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study. Published online March 26, 2020. Accessed March 26, 2020.
  2. Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019. Published online March 26, 2020. Accessed March 26, 2020.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication